HighField Biopharmaceuticals
  • Home
  • Platforms
    • ADCplex Platform
    • TCEplex Platform
    • tLNPplex Platform
  • Pipeline
    • K16: Immune Modulator
    • K1: Lipid-based Antibody Drug Complex
    • HF50: T cell Engager
    • HFG!: GLP-1R Agonist
  • Facilities
  • About
  • News & Publications
  • Contact
  • zh_CN简体中文
HighField Biopharmaceuticals
  • Home
  • Platforms
    • ADCplex Platform
    • TCEplex Platform
    • tLNPplex Platform
  • Pipeline
    • K16: Immune Modulator
    • K1: Lipid-based Antibody Drug Complex
    • HF50: T cell Engager
    • HFG!: GLP-1R Agonist
  • Facilities
  • About
  • News & Publications
  • Contact
  • zh_CN简体中文

Search Posts

About Us

Lorem ipsum dolor sit amet, consectetur adipisc
glelit, sed do eiusmod tempor incididunt .ut labo
et dolore magna aliqua.

Blog Categories

  • HighField in the News (4)
  • Press Release (18)
  • Publications (16)
  • References (21)
  • Uncategorized (6)
  • Video (1)

Recent Posts

December 4, 2025

HighField Biopharmaceuticals Presents Clinical Trial Sample Analysis of 2 Novel Lipid-Based Immuno-Oncology Therapeutics at the Society for Immunotherapy of Cancer (SITC) 2025 Meeting

by PJWCreative
Post placeholder image
November 9, 2025

SITC 2025 Poster: Targeting MDSCs with HF1K16 Unlocks Long-Term Survival in Refractory Recurrent Glioma: an update of NCT05388487

by HighField Bio
Post placeholder image
November 9, 2025

SITC 2025 Poster: First-in-Human Evaluation of HF50, a Novel Liposomal HER2xCD3 T Cell Engager with TLR Agonist Payload, Demontrates Tolerability and Early Clinical Response

by HighField Bio
October 31, 2025

Clinical Data of Two HighField Biopharmaceuticals Immuno-Oncology Lipid-Based Therapeutics Accepted for Late-Breaking Abstract Presentations at the 40th Anniversary Meeting of the Society for Immunotherapy of Cancer (SITC) Nov. 5 – 9, 2025.

by HighField Bio
Post placeholder image
July 31, 2025

Video 1 Test

by PJWCreative
April 21, 2025

HighField Biopharmaceuticals Files INDs for Two ADCplex™ Immunoliposomes with Different Cancer Killing Payloads to Overcome Limitations of Current ADCs

by HighField Bio

Recent Comments

No comments to show.

Tags

General HF50 HFG1 K1 K16

https://highfieldbio.com/wp-content/uploads/2025/07/HIGHFIELD_VideoADC2_Final-1.mp4
July 31, 2025 in Video

Video 1 Test

PJWCreative 0 Like Post 0 Comment

https://highfieldbio.com/wp-content/uploads/2025/07/HIGHFIELD_VideoADC2_Final-1.mp4  

Read More

Download Company Profile

Home
Platforms
Pipeline
Facilities
About
News & Publications

Contact Us

Follow Us

Linkedin Weixin

© 2023-25 HighField Biopharmaceuticals, Inc.   Terms of Use.       
LipoADCplex™ and TRAFsome™ are trademarks of HighField Biopharmaceuticals, Inc

en_US English
en_US English
zh_CN 简体中文